Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Trial Details

NCT ID

NCT06830031

Phase

PHASE1

Sponsor

Shanghai Exuma Biotechnology Ltd.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• C402-CD19-CAR

Locations (sample)

• Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

• Must meet all the following inclusion criteria:
• Male or female 18-75 years (inclusive);
• Patients can understand this study and capable of providing informed consent;
• Patients with willingness to be in the study and comply with the study visit procedures and other protocol requirements;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.